Canada:
Millennium And Janssen Seek Leave From Supreme Court Of Canada In Section 8 Bortezomib Case
05 February 2020
Smart & Biggar
To print this article, all you need is to be registered or login on Mondaq.com.
As
previously reported, the Federal Court of Appeal (FCA)
dismissed Millennium Pharmaceuticals and Janssen's appeal from
a decision granting Teva's claim for compensation under section
8 of the Patented Medicines (Notice of Compliance)
Regulations relating to Teva's bortezomib product (Janssen
markets bortezomib as VELCADE). The FCA upheld
Justice Locke's finding that Teva would not have infringed
Patents Nos. 2,203,936 and 2,435,146 because their relevant claims were
invalid for obviousness. On January 3, 2020, Millenium
Pharmaceuticals and Janssen applied to the Supreme Court of Canada
for leave to appeal (Docket No. 39007).
The preceding is intended as a timely update on Canadian
intellectual property and technology law. The content is
informational only and does not constitute legal or professional
advice. To obtain such advice, please communicate with our offices
directly.
POPULAR ARTICLES ON: Intellectual Property from Canada
"Bad Faith" As A Ground Of Opposition
Goldman Sloan Nash & Haber LLP
A decision of the Federal Court has dismissed an appeal from a decision of the Trademark Opposition Broad. (Spirit Bear Coffee Company Inc. v. Kitasoo First Nation 2023 FC 1185).
15% Or 20% Longer Lasting
Goldman Sloan Nash & Haber LLP
A recent decision of the Federal Court provides a detailed review of alleged comparative advertising. Energizer Brands, LLC v. Gillette Company 2023 FC 804...
Protecting The Bitcoin File Format
Goldman Sloan Nash & Haber LLP
A decision of the UK Court of Appeal has found that copyright likely subsists in the Bitcoin File Format and provides a detailed summary of the concept of fixation in copyright law.